Compare Direxion NASDAQ 100 Equal Weighted Index Shares (QQQE) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Direxion NASDAQ 100 Equal Weighted Index Shares vs Recursion Pharmaceuticals Inc — how do they compare? Direxion NASDAQ 100 Equal Weighted Index Shares trades at $117.32, while Recursion Pharmaceuticals Inc trades at $3 (market cap $1.63B). The key difference: Direxion NASDAQ 100 Equal Weighted Index Shares is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| QQQE | RXRX | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $122.72 | $6.79 |
52-Week Low | $96.06 | $2.84 |
Market Cap | — | $1.63B |
Enterprise Value | — | $1.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QQQE trades at $116.70, down 0.09% on the day, with a mixed technical signal showing a bullish overall trend but bearish moving averages. The ETF offers equal-weighted exposure to the Nasdaq-100, reducing concentration risk compared to cap-weighted peers. Recent news highlights its appeal as a diversified alternative amid high market concentration, with SpaceX's upcoming Nasdaq-100 inclusion potentially driving passive inflows.
The outlook for QQQE is positive due to its defensive structure and uncorrelated performance, though technical indicators suggest near-term consolidation. Key risks include market volatility and reliance on growth stocks. Analyst sentiment is constructive, emphasizing its role in balanced Nasdaq exposure.
Recursion Pharmaceuticals (RXRX) trades at $2.89, down 1.87% with a bearish technical signal despite recent earnings beats. The company shows significant revenue growth challenges with 2025 revenue of $74.26M but massive losses of -$644.76M, resulting in a -851.51% net margin. Analyst sentiment is mixed with 40% buy ratings but a consensus price target of $7.83, representing 171% upside potential from current levels.
While RXRX offers substantial upside based on analyst targets, the stock carries high risk due to persistent losses, negative cash flow from operations, and unproven AI-driven drug discovery platform. The company's heavy reliance on financing activities to fund operations presents ongoing dilution risk, making this suitable only for risk-tolerant investors betting on long-term biotech breakthroughs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Direxion NASDAQ 100 Equal Weighted Index Shares
QQQE is an ETF that seeks to track the performance of the NASDAQ-100 Equal Weighted Index. Unlike traditional market-capitalization-weighted indexes, this fund assigns equal weight to each of the 100 non-financial companies in the NASDAQ-100 and rebalances quarterly. This equal-weighting scheme reduces concentration risk in the largest technology companies and increases the fund's exposure to smaller-cap and mid-cap companies within the index, providing a differentiated growth profile.
Read more on QQQE →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
